menu search

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with approximately $194.6 million in cash and cash equivalents Initiated two Phase 2 trials, AURORA and BEACON, for bitopertin in erythropoietic protoporphyria (EPP); initial BEACON data to be shared 1H 2023 and topline AURORA data expected by end of 2023 Completed […] The post Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update appeared first on ForexTV... Read More
Posted: Mar 31 2023, 11:00
Author Name: forextv
Views: 110128

Search within

Pages Search Results: